Related Experiment Video
Updated: Jul 16, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells
Taiping Chen1, Sarah Hevi, Frédérique Gay
1Epigenetics Program, Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.
Abstract:
Studies have shown that DNA (cytosine-5-)-methyltransferase 1 (DNMT1) is the principal enzyme responsible for maintaining CpG methylation and is required for embryonic development and survival of somatic cells in mice. The role of DNMT1 in human cancer cells, however, remains highly controversial. Using homologous recombination, here we have generated a DNMT1 conditional allele in the human colorectal carcinoma cell line HCT116 in which several exons encoding the catalytic domain are flanked by loxP sites. Cre recombinase-mediated disruption of this allele results in hemimethylation of approximately 20% of CpG-CpG dyads in the genome, coupled with activation of the G2/M checkpoint, leading to arrest in the G2 phase of the cell cycle. Although cells gradually escape from this arrest, they show severe mitotic defects and undergo cell death either during mitosis or after arresting in a tetraploid G1 state. Our results thus show that DNMT1 is required for faithfully maintaining DNA methylation patterns in human cancer cells and is essential for their proliferation and survival.
Insights
DNA methyltransferase 1 (DNMT1) is crucial for maintaining DNA methylation patterns in human cancer cells. Its disruption causes cell cycle arrest, mitotic defects, and cell death, highlighting DNMT1
Area of Science:
- Molecular Biology
- Epigenetics
- Cancer Biology
Background:
- DNA (cytosine-5-)-methyltransferase 1 (DNMT1) is essential for maintaining CpG methylation in mice.
- The function of DNMT1 in human cancer cells is controversial and requires further investigation.
Purpose of the Study:
- To investigate the role of DNMT1 in maintaining DNA methylation and its impact on cell proliferation and survival in human cancer cells.
Main Methods:
- Generated a DNMT1 conditional allele in HCT116 colorectal carcinoma cells using homologous recombination.
- Utilized Cre recombinase to disrupt the DNMT1 allele, leading to hemimethylation of CpG sites.
- Analyzed cell cycle progression, mitotic fidelity, and cell death following DNMT1 disruption.
Main Results:
- DNMT1 disruption resulted in hemimethylation of approximately 20% of CpG-CpG dyads.
- Cells exhibited G2/M checkpoint activation and G2 phase arrest.
- Cells displayed severe mitotic defects and subsequent cell death or tetraploid G1 arrest.
Conclusions:
- DNMT1 is essential for maintaining DNA methylation patterns in human cancer cells.
- DNMT1 plays a critical role in ensuring cell proliferation and survival.
- Targeting DNMT1 may represent a therapeutic strategy for colorectal carcinoma.
More Related Videos
08:34Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
Published on: April 13, 2015
08:33Combining Mitotic Cell Synchronization and High Resolution Confocal Microscopy to Study the Role of Multifunctional Cell Cycle Proteins During Mitosis
Published on: December 5, 2017
Related Concept Videos
Abnormal Proliferation
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...